Bayer to deploy Phylo’s Biomni Lab AI platform

Phylo, Inc. announced on October 22, 2026, a partnership with Bayer to deploy Biomni Lab, Phylo’s agentic AI platform, to accelerate scientific research and evaluation. Under the agreement, Phylo will provide Bayer with full access to its agentic platform, expanding the use of AI agents in Bayer’s scientific research activities.

The collaboration is designed to support Bayer scientists by integrating scientific literature, biomedical data, and analytical methods into a single environment. By centralizing these elements, the platform seeks to reduce the manual effort required to assemble and assess scientific evidence within Bayer’s research programs.

Bayer scientists will gain access to Biomni Lab for workflows focused on assembling literature and omics evidence for drug discovery. The platform’s agentic architecture allows scientists to work with AI agents that help coordinate data gathering, analysis, and interpretation across complex research questions.

A defining feature of Biomni Lab is its inspectable workflows, which preserve the context behind each result. Researchers can review underlying sources, analytical methods, and execution steps, helping them apply their own scientific judgment to AI-supported findings.

Within this unified environment, scientists can collaborate with AI agents across literature research, experimental design, biological data analysis, and scientific decision-making. The aim is to create a workspace where evidence is assembled transparently and can be scrutinized in detail.

Bayer’s leadership described the partnership as aligned with a view that AI should expand scientific curiosity as well as support routine work. Sai Jasti, Senior Vice President and Head of Data Science & Artificial Intelligence at Bayer Pharmaceuticals R&D, emphasized the goal of giving scientists an AI partner that brings rigor to each step of research, enabling them to explore more ideas and ask bolder questions.

Kexin Huang, Ph.D., Co-Founder and CEO of Phylo, highlighted that for agentic AI to matter in research it must earn the trust of scientists conducting the work. Bayer’s selection of Biomni Lab was presented as an endorsement of the platform’s scientific rigor and AI capabilities, and aligned with Phylo’s vision of an AI-native operating system for biopharma where scientists can direct teams of AI agents.

Phylo describes its mission as bringing agentic intelligence to biomedical scientists through an enterprise-grade AI platform. Phylo describes Biomni Lab as the first Integrated Biology Environment, offering a unified workspace for collaboration between scientists and AI agents across multiple stages of biomedical research.

Biomni Lab is already in use at several global biopharma companies, including Bayer, Chugai Pharmaceutical, and Ono Pharmaceutical. Phylo is based in South San Francisco and is backed by investors including Andreessen Horowitz and Menlo Ventures, supporting the further development and deployment of its agentic AI technologies.